SEER Inquiry System - Question 20061017 Details

System Guide

Back to Search Results

SEER Inquiry System - Report

Produced: 11/18/2025 5:49 AM

Question 20061017

Export CSV Export PDF Print

Add to Report

Inquiry Details

References:

2004 SEER Manual, C-553 to C-556

Question:

CS Eval--Prostate: How is CS Ts/Ext Eval to be coded for a clinically inapparent prostate cancer that is treated with Lupron and a subsequent prostatectomy? See Discussion.

Discussion:

Patient diagnosed with prostate cancer on biopsy for elevated PSA, CS extension code 15. Patient then receives 4 courses of Lupron. Subsequent radical prostatectomy shows bilateral lobe involvement with capsule invasion, SSF 3 pathologic extension code 032.

Answer:

This answer was provided in the context of CSv1 coding guidelines. The response may not be used after your registry database has been converted to CSv2.

Code CS TS/Ext Eval 6 [surgical resection performed with pre-surgical systemic treatment, tumor size/ext based on path evidence]. For prostate, CS TS/Ext eval must reflect coding of CS extension and SSF 3. In this case, SSF 3 code 032 is based on the prostatectomy information which occurred after systemic treatment.

Cancer Site Category:

Prostate

Data Item Category:

N/A

Other Category:

N/A

Year:

2006